Cargando…

597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy

BACKGROUND: Vancomycin and daptomycin are commonly used in outpatient parenteral antimicrobial therapy (OPAT) for patients requiring lengthy courses of intravenous antimicrobials who are otherwise stable for discharge. Balancing the convenience and cost-savings of OPAT with the potential for adverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakrani, Monark, Yu, Diana, Sikka, Monica, Lewis, James, Douglass, Alyse, Mayer, Heather, Young, Kathleen, Streifel, Amber C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777184/ http://dx.doi.org/10.1093/ofid/ofaa439.791

Ejemplares similares

757 Comparison of Nephrotoxicity in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Beta-lactams or Vancomycin
por: Streifel, Amber, et al.
Publicado: (2014)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

1762. A Review of Antibiotic Outcomes Data Utilizing the Multidisciplinary OPTIONS-DC Conference for PWUD
por: Douglass, Alyse H, et al.
Publicado: (2022)

Vancomycin or Daptomycin for Outpatient Parenteral Antibiotic Therapy: Does It Make a Difference in Patient Satisfaction?
por: Wu, Katherine H, et al.
Publicado: (2021)

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs
por: Douglass, Alyse H., et al.
Publicado: (2023)

Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration
por: Britt, Rachel S, et al.
Publicado: (2019)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
por: Martone, W J, et al.
Publicado: (2008)

1923. OPAT or No-PAT? Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Daptomycin or Ertapenem for “Ease of Administration”
por: Britt, Rachel S, et al.
Publicado: (2018)

608. Continuous Infusion Vancomycin Is Not Associated with Improved Safety in an Outpatient Parenteral Antimicrobial Therapy Program
por: Tagare, Rosemarie D, et al.
Publicado: (2021)

Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin vs. Non-Vancomycin Anti-MRSA Therapy
por: Stoneking, Carolyn, et al.
Publicado: (2017)

1298 Predictors of Hospital Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Means, Laura, et al.
Publicado: (2014)

1925. Vancomycin Treatment and Time to Adverse Drug Reactions During Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Duncan, Asajah, et al.
Publicado: (2018)

610. Incidence of Acute Kidney Injury in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin
por: Hamad, Yasir, et al.
Publicado: (2020)

604. Factors Associated with Adverse Drug Reactions Leading to Discontinuation of Vancomycin in Outpatient Parenteral Antimicrobial Therapy
por: McDonald, Josh, et al.
Publicado: (2020)

In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci
por: Tong, Jiepeng, et al.
Publicado: (2021)

OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)

Outpatient parenteral antimicrobial therapy in Brazil
por: Oliveira, Priscila R, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Vancomycin Continuous Infusion in Patients Treated at Home in an Outpatient Parenteral Antimicrobial Therapy Program
por: Thijs, Lore, et al.
Publicado: (2022)

742. The Development, Implementation, and Feasibility of Multidisciplinary Treatment Planning Conference for Individuals with Unstable Substance Use Disorders and Active Infections Requiring Prolonged Antimicrobial Therapy: The OPTIONS-DC Model
por: Strnad, Luke, et al.
Publicado: (2019)

Patient outcomes following home-based outpatient parenteral antimicrobial therapy and facility-based outpatient parenteral antimicrobial therapy: a systematic review and meta-analysis
por: Hasegawa, Shinya, et al.
Publicado: (2023)

234. Dalbavancin versus Outpatient Parenteral Antimicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

329. Vancomycin area under the concentration-time curve monitoring from Bayesian modeling in outpatient parenteral antimicrobial therapy
por: Gillett, Eric M, et al.
Publicado: (2023)

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

1935. Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
por: Blaskewicz, Caitlin, et al.
Publicado: (2018)

Safety of Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
por: Shrestha, Nabin K, et al.
Publicado: (2020)

Recommendations for outpatient parenteral antimicrobial therapy in Brazil
por: Oliveira, Priscila R., et al.
Publicado: (2017)

Assessment of risk factors associated with outpatient parenteral antimicrobial therapy complications
por: Kaul, Christina, et al.
Publicado: (2022)

Decreased hospital readmissions after programmatic strengthening of an outpatient parenteral antimicrobial therapy (OPAT) program
por: Agnihotri, Gaurav, et al.
Publicado: (2023)

Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy
por: Mahoney, Monica V., et al.
Publicado: (2021)

600. Decreased Hospital Readmission After Programmatic Strengthening of an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program
por: Agnihotri, Gaurav, et al.
Publicado: (2020)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy
por: Rehm, Susan, et al.
Publicado: (2009)

In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus faecalis
por: Yu, Wei, et al.
Publicado: (2020)

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas
por: Pertel, P E, et al.
Publicado: (2009)

Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
por: Narayanan, Navaneeth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_up1rioa9j0hb2lf7j73qabk6kj